Esperas Pharma Inc., Montréal, is a special purpose company created to develop one compound to proof-of-concept. The project is fully financed by TVM Life Science Ventures VII and Fonds de solidarité FTQ. Esperas Pharma Inc. plans to begin clinical development as early as Q1-2016. Once cleared for clinical development by regulatory authorities, the Esperas Pharma Inc. compound will be tested directly alone and in combination with gemcitabine in women with triple-negative breast cancer.
Later on, the compound may be tested in one of a number of additional cancer indications with the goal of providing a clinical proof-of-concept of efficacy for cancer patients. Esperas Pharma Inc. is funded by TVM Life Science Ventures VII and the Fonds, and is led by an experienced management team.